TG Therapeutics Toekomstige groei
Future criteriumcontroles 4/6
TG Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 11% en 21.6% per jaar. De winst per aandeel zal naar verwachting groeien met 7.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 56.9% zijn.
Belangrijke informatie
11.0%
Groei van de winst
7.48%
Groei van de winst per aandeel
| Biotechs winstgroei | 23.5% |
| Inkomstengroei | 21.6% |
| Toekomstig rendement op eigen vermogen | 56.93% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 29 Apr 2026 |
Recente toekomstige groei-updates
Recent updates
TGTX: JPMorgan Cut And Execution Risks Will Pressure Future Upside Potential
Analysts have modestly raised their fair value estimate for TG Therapeutics to about $17.57 per share, from roughly $17.32, citing refreshed assumptions around revenue growth, profit margins, discount rates and future P/E, as well as recent Street research including the latest JPMorgan price target update. Analyst Commentary Recent Street research, including a reduced price target at JPMorgan, points to a more cautious tone around TG Therapeutics, even as fair value estimates move only slightly.TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
Apr 19TGTX: Recent JPMorgan Cut Will Likely Expose Fragile Earnings Expectations
Analysts have adjusted their fair value estimate for TG Therapeutics from $15.49 to $17.32, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E following recent price target revisions, including the $3 cut highlighted by JPMorgan. Analyst Commentary Recent commentary around TG Therapeutics has tilted cautious, with the $3 price target cut at JPMorgan reinforcing a more conservative stance on both execution and valuation risk.
TGTX: Shares Should Advance As Durable Multiple Sclerosis Data Supports Recovery
Narrative Update The blended analyst price target for TG Therapeutics is now effectively unchanged around $44, as recent moves, including a $3 trim at one firm and modest raises at others, reflect updated views on sector funding conditions, deal activity, and regulatory risk, while leaving core assumptions on growth, margins, and future P/E largely intact. Analyst Commentary Recent Street research around TG Therapeutics has been active but mixed, with one major firm trimming its target while others lift theirs, leaving the blended target roughly unchanged.TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Drives Confidence
Analysts recently adjusted their price targets for TG Therapeutics in a mixed way, with one firm cutting its target by $3 while others raised theirs by $2 and $2. These changes reflect updated views on sector conditions, access to capital, M&A activity and company specific data catalysts.TGTX: Shares Should Rebound As Long Term Multiple Sclerosis Data Supports Upside
Analysts have nudged their price targets on TG Therapeutics in both directions recently, with moves such as a $3 trim at one firm and a $2 lift at another. These changes reflect updated views on discount rates, revenue growth assumptions, profit margins and future P/E, rather than a wholesale shift in the $44.43 fair value estimate used in this model.TGTX: Shares Should Rebound As Revenue Outlook Supports Mixed Street Views
Analysts have made only a modest adjustment to their TG Therapeutics price targets, reflecting a slightly higher assumed discount rate and marginally lower future P/E expectations, while maintaining a consistent fair value estimate near $44 per share. Analyst Commentary Recent Street research on TG Therapeutics has been mixed, with some firms lifting price targets and others trimming them.TGTX: Shares Should Rebound As Mixed Street Views Contrast With Strong Revenue Outlook
Analysts have adjusted their blended price target on TG Therapeutics slightly lower, trimming fair value by about $0.43 to reflect updated assumptions around growth, margins and future P/E following a mix of recent target revisions from major firms. Analyst Commentary Recent Street research on TG Therapeutics reflects a mix of optimism on the setup for biotech and specific caution around the company’s execution and valuation, which is feeding into the modest trim in the blended price target.TGTX: Shares Should Rebound As Revenue Outlook Strengthens On Updated Guidance
Narrative Update Analysts have nudged their price target for TG Therapeutics higher to about $44.86, up from roughly $44.29. This reflects updated earnings models that incorporate slightly higher profit margin assumptions, a modestly adjusted discount rate and a small change to expected future P/E levels following recent Street research, including target increases from BofA, Goldman Sachs and JPMorgan.TGTX: Higher JPMorgan Price View Will Likely Overstate Future Earnings Delivery
TG Therapeutics' analyst price target has moved higher, with a recent US$3 increase to US$49 as analysts refreshed their models after the latest earnings update. Analyst Commentary The latest move to a US$49 price target from JPMorgan signals that at least one major firm has refreshed its view following the recent earnings update, with a focus on updated assumptions in its valuation model.
TGTX: Higher Earnings Visibility Will Support A Re-Rating Over Time
Analysts have lifted their price target on TG Therapeutics shares, raising fair value by about $7 per share to $60, as updated post earnings models factor in a higher future P/E multiple despite slightly lower growth and margin assumptions. Analyst Commentary Following the latest earnings update, bullish analysts are increasingly highlighting TG Therapeutics as a beneficiary of improving fundamentals and greater earnings visibility, which they see as supporting a higher valuation range over the medium term.TGTX: Shares Will Likely Rebound As Long Term Sales Milestone Approaches
Analysts have modestly raised their blended price target for TG Therapeutics, reflecting increased confidence in multi year Briumvi growth and updated post earnings models that point to a path toward more than $1 billion in annual sales. Analyst Commentary Recent Street updates reflect a predominantly constructive stance on TG Therapeutics, with upwardly revised price targets and reinforced positive ratings following the latest earnings update.TGTX: Shares Will Likely Rebound Following Recent Buyback And Earnings Dip
Analysts have raised their price targets for TG Therapeutics, with recent updates reflecting increases of $3 to $49 and $2 to $55. This is based on confidence in ongoing sales growth and an improved margin outlook following the company's earnings report.TGTX: Shares Will Likely See Renewed Momentum With Expanding U.S. Drug Adoption
Analysts have modestly increased their price target for TG Therapeutics, raising it from approximately $43.57 to $44.29. This adjustment is due to optimism about multi-year sales growth for Briumvi and updated post-earnings forecasts.TG Therapeutics (NASDAQ:TGTX) Takes On Some Risk With Its Use Of Debt
Oct 23
Analyst Commentary Drives Optimism for TG Therapeutics as Briumvi Growth Fuels Higher Price Targets
Narrative Update on TG Therapeutics Analysts have raised their price target for TG Therapeutics by $2 to $55. They cite expectations for sustained multi-year sales growth, supported by strong prospects for Briumvi in the U.S. market.A Subcutaneous Launch Will Unlock The Anti-CD20 MS Market
Analysts have raised their price target for TG Therapeutics from $40.50 to $43.57, citing expectations of sustained Briumvi sales growth and an improved revenue outlook. Analyst Commentary Recent Street research highlights a range of perspectives regarding TG Therapeutics, with particular focus on Briumvi's market performance and growth trajectory.What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You
Sep 30Revenues Not Telling The Story For TG Therapeutics, Inc. (NASDAQ:TGTX)
Jul 29TG Therapeutics' (NASDAQ:TGTX) Weak Earnings May Only Reveal A Part Of The Whole Picture
May 16TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
Mar 14TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
Nov 05
BRIUMVI's Breakthrough In MS Market Promises Robust Revenue Surge And Expanding Therapeutic Horizons
Strong sales of BRIUMVI and strategic expansions such as innovative versions aim to secure market dominance in treating relapsing multiple sclerosis.TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics: Less Room For Doubt About Briumvi
May 03Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,478 | 427 | 476 | 505 | 4 |
| 12/31/2027 | 1,145 | 374 | 407 | 450 | 7 |
| 12/31/2026 | 900 | 230 | 240 | 216 | 8 |
| 12/31/2025 | 616 | 447 | -25 | -25 | N/A |
| 9/30/2025 | 532 | 447 | -70 | -70 | N/A |
| 6/30/2025 | 454 | 60 | -59 | -59 | N/A |
| 3/31/2025 | 386 | 39 | -61 | -61 | N/A |
| 12/31/2024 | 329 | 23 | -41 | -41 | N/A |
| 9/30/2024 | 265 | -14 | -28 | -28 | N/A |
| 6/30/2024 | 347 | 96 | 68 | 68 | N/A |
| 3/31/2024 | 289 | 41 | 20 | 20 | N/A |
| 12/31/2023 | 234 | 13 | -31 | -31 | N/A |
| 9/30/2023 | 190 | -26 | -42 | -42 | N/A |
| 6/30/2023 | 24 | -176 | -160 | -160 | N/A |
| 3/31/2023 | 9 | -169 | -167 | -167 | N/A |
| 12/31/2022 | 3 | -224 | -176 | -176 | N/A |
| 9/30/2022 | 5 | -239 | -239 | -239 | N/A |
| 6/30/2022 | 7 | -288 | -272 | -272 | N/A |
| 3/31/2022 | 8 | -326 | -283 | -283 | N/A |
| 12/31/2021 | 7 | -348 | -296 | -296 | N/A |
| 9/30/2021 | 4 | -343 | -261 | -261 | N/A |
| 6/30/2021 | 2 | -345 | -251 | -250 | N/A |
| 3/31/2021 | 1 | -319 | -234 | -234 | N/A |
| 12/31/2020 | 0 | -279 | -215 | -215 | N/A |
| 9/30/2020 | 0 | -231 | -193 | -193 | N/A |
| 6/30/2020 | 0 | -206 | -170 | -170 | N/A |
| 3/31/2020 | 0 | -189 | -162 | -162 | N/A |
| 12/31/2019 | 0 | -173 | -133 | -133 | N/A |
| 9/30/2019 | 0 | -187 | N/A | -136 | N/A |
| 6/30/2019 | 0 | -159 | N/A | -136 | N/A |
| 3/31/2019 | 0 | -167 | N/A | -134 | N/A |
| 12/31/2018 | 0 | -173 | N/A | -129 | N/A |
| 9/30/2018 | 0 | -150 | N/A | -117 | N/A |
| 6/30/2018 | 0 | -148 | N/A | -107 | N/A |
| 3/31/2018 | 0 | -132 | N/A | -100 | N/A |
| 12/31/2017 | 0 | -118 | N/A | -94 | N/A |
| 9/30/2017 | 0 | -111 | N/A | -89 | N/A |
| 6/30/2017 | 0 | -105 | N/A | -81 | N/A |
| 3/31/2017 | 0 | -92 | N/A | -67 | N/A |
| 12/31/2016 | 0 | -78 | N/A | -62 | N/A |
| 9/30/2016 | 0 | -72 | N/A | -57 | N/A |
| 6/30/2016 | 0 | -61 | N/A | -53 | N/A |
| 3/31/2016 | 0 | -62 | N/A | -52 | N/A |
| 12/31/2015 | 0 | -63 | N/A | -45 | N/A |
| 9/30/2015 | 0 | -64 | N/A | -47 | N/A |
| 6/30/2015 | 0 | -68 | N/A | -44 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei TGTX ( 11% per jaar) ligt boven de spaarquote ( 3.4% ).
Winst versus markt: De winst van TGTX ( 11% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 16% per jaar).
Hoge groeiwinsten: De winst van TGTX zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van TGTX ( 21.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 11.2% per jaar).
Hoge groei-inkomsten: De omzet van TGTX ( 21.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen TGTX zal naar verwachting over 3 jaar zeer hoog zijn ( 56.9 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/04 13:26 |
| Aandelenkoers aan het einde van de dag | 2026/05/01 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
TG Therapeutics, Inc. wordt gevolgd door 18 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Alec Stranahan | BofA Global Research |
| William Wood | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |